These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 26198005)

  • 21. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
    Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
    Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
    Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
    J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of aurora kinases inhibitors based on N-trisubstituted pyrimidine scaffold.
    Long L; Luo Y; Hou ZJ; Ma HJ; Long ZJ; Tu ZC; Huang LJ; Liu Q; Lu G
    Eur J Med Chem; 2018 Feb; 145():805-812. PubMed ID: 29358147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
    Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
    Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
    Jing L; Tang Y; Xiao Z
    Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
    Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
    Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
    Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
    Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
    Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
    Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
    Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
    ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.
    Abadi AH; Abou-Seri SM; Abdel-Rahman DE; Klein C; Lozach O; Meijer L
    Eur J Med Chem; 2006 Mar; 41(3):296-305. PubMed ID: 16494969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
    Lee J; Park T; Jeong S; Kim KH; Hong C
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1284-7. PubMed ID: 17178224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.
    Morioka M
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5860-5862. PubMed ID: 27884697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological activity of N
    Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.
    Fan C; Zhong T; Yang H; Yang Y; Wang D; Yang X; Xu Y; Fan Y
    Eur J Med Chem; 2020 Mar; 190():112108. PubMed ID: 32058239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS; Ismail NS; Elzahabi HS
    Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization and biological evaluation of nicotinamide derivatives as Aurora kinase inhibitors.
    Qi B; Xu X; Yang Y; He H; Yue X
    Bioorg Med Chem; 2019 Sep; 27(17):3825-3835. PubMed ID: 31307762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
    Yun F; Cheng C; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Jul; 198():112322. PubMed ID: 32361064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.